Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection.
NETest
Neuroendocrine tumour
Small bowel
Surgery
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
25
01
2020
accepted:
25
03
2020
pubmed:
16
4
2020
medline:
22
6
2021
entrez:
16
4
2020
Statut:
ppublish
Résumé
Surgical resection is the only effective curative strategy for small intestinal neuroendocrine neoplasms (SINENs). Nevertheless, the evaluation of residual disease and prediction of disease recurrence/progression remains a problematic issue. We evaluated 13 SINENs that underwent surgical resection of the primary tumour and/or mesenteric mass. Patients were divided in three groups: (a) Group 1: SINENs that underwent resection with curative intent, (b) Group 2: SINENs treated with resection in the setting of metastatic disease, which remained stable and (c) Group 3: SINENs treated with resection in the setting of metastatic disease, with evidence of any progression at follow-up. NETest and chromogranin A were measured pre-operatively and post-operatively during a 22-month median follow-up period and compared with imaging studies. NETest score <20% was determined as normal, 20-40% low, 41-79% intermediate and ≥80% high score. NETest score was raised in all (100%) SINENs pre-operatively. Surgery with curative intent resulted in NETest score reduction from 78.25 ± 15.32 to 25.25 ± 1.75 (p < 0.05). Low NETest scores post-operatively were evident in all cases without clinical evidence of residual disease (Group 1). However, the low disease activity score suggested the presence of microscopic residual disease. In three cases (75%) with stable disease (Group 2) the NETest score was low consistent with indolent disease. In the progressive disease group (Group 3), a high NETest score was present in three cases (60%) and an intermediate NETest score in the remainder (40%). Blood NETest scores accurately identified SINENs and were significantly decreased by curative surgery. Monitoring NETest post-operatively may facilitate management by identifying the presence of residual/progressive disease.
Identifiants
pubmed: 32291735
doi: 10.1007/s12020-020-02289-2
pii: 10.1007/s12020-020-02289-2
pmc: PMC7392928
doi:
Substances chimiques
Biomarkers, Tumor
0
Chromogranin A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
430-440Références
M. Pavel, D. O’Toole, F. Costa et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2), 172–185 (2016). https://doi.org/10.1159/000443167
pubmed: 26731013
doi: 10.1159/000443167
V.T.F. Cheung, M.S. Khan, A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome. Frontline Gastroenterol. 6(4), 264–269 (2015). https://doi.org/10.1136/flgastro-2014-100483
pubmed: 28839822
doi: 10.1136/flgastro-2014-100483
A.T. Scott, J.R. Howe, Management of small bowel neuroendocrine tumors. J. Oncol. Pr. 14(8), 471–482 (2018). https://doi.org/10.1200/JOP.18.00135
doi: 10.1200/JOP.18.00135
L.R. Woodbridge, B.M. Murtagh, D.F. Yu, K.L. Planche, Midgut neuroendocrine tumors: imaging assessment for surgical resection. Radiographics 34, 413–426 (2014). https://doi.org/10.1148/rg.342135504
pubmed: 24617688
doi: 10.1148/rg.342135504
J. Capdevila, O. Casanovas, R. Salazar, et al. Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene 36, 1899–1907 (2017). https://doi.org/10.1038/onc.2016.316
pubmed: 27641330
doi: 10.1038/onc.2016.316
K. Oberg, I. Modlin, W. DeHerder et al. Biomarkers for neuroendocrine tumor disease: a delphic consensus assessment of multianalytes, genomics, circulating cells and monoanalytes. Lancet Oncol. 16, e435046 (2015)
doi: 10.1016/S1470-2045(15)00186-2
C.G. Genc, A.P. Jilesen, S. Partelli, et al. A new scoring system to predict recurrent disease in grade 1 and 2 nonfunctional pancreatic neuroendocrine tumors. Ann. Surg. 267(6), 1148–1154 (2018). https://doi.org/10.1097/SLA.0000000000002123
pubmed: 28594340
doi: 10.1097/SLA.0000000000002123
F.M. Laskaratos, M. Walker, D. Wilkins et al. Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours. Neuroendocrinology 107(3), 292–304 (2018). https://doi.org/10.1159/000493317
pubmed: 30153671
doi: 10.1159/000493317
C. Toumpanakis, M.K. Kim, A. Rinke et al. Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 21, 21 (2014)
I.M. Modlin, B.I. Gustafsson, S.F. Moss, M. Pavel, A.V. Tsolakis, M. Kidd, Chromogranin A—biological function and clinical utility in neuro endocrine tumor disease. Ann. Surg. Oncol. 17, 2427–2443 (2010)
pubmed: 20217257
doi: 10.1245/s10434-010-1006-3
V. Marotta, V. Nuzzo, T. Ferrara et al. Limitations of chromogranin A in clinical practice. Biomarkers 17(2), 186–191 (2012). https://doi.org/10.3109/1354750X.2012.654511
pubmed: 22303881
doi: 10.3109/1354750X.2012.654511
A. Walenkamp, G. Crespo, F. Fierro Maya et al. Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. Endocr. Relat. Cancer 21(6), R445–R460 (2014). https://doi.org/10.1530/ERC-14-0106
pubmed: 25296914
doi: 10.1530/ERC-14-0106
K. Oberg, E. Krenning, A. Sundin et al. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr. Connect. 5(5), 174–187 (2016). https://doi.org/10.1530/EC-16-0043
pubmed: 27582247
pmcid: 5045519
doi: 10.1530/EC-16-0043
E. Liu, S. Paulson, A. Gulati, et al. Assessment of NETest Clinical utility in a US registry-based study. Oncologist 24(6), 783–790 (2019).
pubmed: 30158287
doi: 10.1634/theoncologist.2017-0623
I.M. Modlin, H. Aslanian, L. Bodei, I. Drozdov, M. Kidd, APCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by PPIs. Endocr. Connect. 3, 215–223 (2014).
pubmed: 25316294
doi: 10.1530/EC-14-0100
I.M. Modlin, M. Kidd, L. Bodei, I. Drozdov, H. Aslanian,, The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. Am. J. Gastroenterol. 110(8), 1223–1232 (2015). https://doi.org/10.1038/ajg.2015.160
pubmed: 26032155
doi: 10.1038/ajg.2015.160
I.M. Modlin, M. Kidd, A. Malczewska et al. The NETest: the clinical utility of multigene blood analysis in the diagnosis and management of neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 47(3), 485–504 (2018). https://doi.org/10.1016/j.ecl.2018.05.002
pubmed: 30098712
pmcid: 6716518
doi: 10.1016/j.ecl.2018.05.002
M. Kidd, I.A. Drozdov, S. Matar et al. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. PLoS ONE 14(6), e0218592 (2019). https://doi.org/10.1371/journal.pone
pubmed: 31247038
pmcid: 6597157
doi: 10.1371/journal.pone
M. Kidd, I. Drozdov, I. Modlin, Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocr. Relat. Cancer 22(4), 561–575 (2015). https://doi.org/10.1530/ERC-15-0092
pubmed: 26037279
doi: 10.1530/ERC-15-0092
M.J.C. van Treijen, C.M. Korse, R.S. van Leeuwaarde et al. Blood transcript profiling for the detection of neuroendocrine tumors: results of a large independent validation study. Front. Endocrinol. 9, 740 (2018). https://doi.org/10.3389/fendo.2018.00740
doi: 10.3389/fendo.2018.00740
A. Malczewska, L. Bodei, M. Kidd, I.M. Modlin, Blood mRNA measurement (NETest) for neuroendocrine tumor diagnosis of image-negative liver metastatic disease. J. Clin. Endocrinol. Metab. 104(3), 867–872 (2019). https://doi.org/10.1210/jc.2018-01804
pubmed: 30358858
doi: 10.1210/jc.2018-01804
F.M. Laskaratos, M. Caplin, Treatment challenges in and outside a network setting: gastrointestinal neuroendocrine tumours. Eur. J. Surg. Oncol. 45(1), 52–59 (2019). https://doi.org/10.1016/j.ejso.2018.03.012
pubmed: 29685756
doi: 10.1016/j.ejso.2018.03.012
E. Hodara, G. Morrison, A. Cunha, et al., Multiparametric liquid biopsy analysis in metastatic prostate cancer. JCI Insight 4(5), 125529 (2019). https://doi.org/10.1172/jci.insight
pubmed: 30702443
doi: 10.1172/jci.insight
C. Massard, M. Oulhen, S. Le Moulec et al. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: a report from the PETRUS prospective study. Oncotarget 7(34), 55069–55082 (2016). https://doi.org/10.18632/oncotarget.0396
pubmed: 27391263
pmcid: 5342402
doi: 10.18632/oncotarget.0396
A. Sharp, J.C. Welti, M.B.K. Lambros, et al. Clinical utility of circulating tumour cell androgen receptor splice variant-7 status in metastatic castration-resistant prostate cancer. Eur. Urol. 76(5), 676–685 (2019).
pubmed: 31036442
doi: 10.1016/j.eururo.2019.04.006
J. Tie, J.D. Cohen, Y. Wang, Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. JAMA Oncol. 5(12), 1710–1717 (2019).
doi: 10.1001/jamaoncol.2019.3616
A. Malczewska, K. Oberg, L. Bodei et al. NETest liquid biopsy is diagnostic of lung neuroendocrine tumors and identifies progressive disease. Neuroendocrinology. 108(3), 219–231 (2019)
pubmed: 30654372
A. Malczewska, M. Witkowska, K. Makulik, et al. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocr. Connect 8(4), 442–453 (2019).
pmcid: 6479193
doi: 10.1530/EC-19-0030
F.M. Laskaratos, D. Mandair, A. Hall, et al. Clinicopathological correlations of mesenteric fibrosis and evaluation of a novel biomarker for fibrosis detection in small bowel neuroendocrine neoplasms. Endocrine. 67(3), 718–726 (2020).
pubmed: 31598848
doi: 10.1007/s12020-019-02107-4
J.B. Cwikla, L. Bodei, A. Kolasinska-Cwikla, A. Sankowski, I.M. Modlin, M. Kidd, Circulating transcript analysis (NETest) in GEP-NETs treated with somatostatin analogs defines therapy. J. Clin. Endocrinol. Metab. 100(11), E1437–E1445 (2015)
pubmed: 26348352
doi: 10.1210/jc.2015-2792
L. Bodei, M.S. Kidd, A. Singh et al. PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. Eur. J. Nucl. Med. Mol. Imaging. 45(7), 1155–1169 (2018)
pubmed: 29484451
pmcid: 6716527
doi: 10.1007/s00259-018-3967-6
M. Pavel, H. Jann, V. Prasad, I. Drozdov, I.M. Modlin, M. Kidd, NET blood transcript analysis defines the crossing of the clinical rubicon: when stable disease becomes progressive. Neuroendocrinology. 104(2), 170–182 (2017)
pubmed: 27078712
doi: 10.1159/000446025
I.M. Modlin, I. Drozdov, D. Alaimo et al. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection. Endocr. Relat. Cancer. 21(4), 615–628 (2014). https://doi.org/10.1530/ERC-14-0190
pubmed: 25015994
doi: 10.1530/ERC-14-0190
P. Filosso, M. Kidd, M. Roffinella, et al.The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumors (BPNET) and as a tool to evaluate surgical resection and disease progression. Eur. J. Cardiothorac. Surg. 53, 631–639 (2018)
pubmed: 29145657
doi: 10.1093/ejcts/ezx386
C. Genc, A.P. Jilesen, E. Nieveen van Dijkum et al. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumours. J. Surg. Oncol. 118(1), 37–48 (2018)
pubmed: 30114319
doi: 10.1002/jso.25129
I.M. Modlin, A. Frilling, R.R. Salem et al. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. 159(1), 336–347 (2016). https://doi.org/10.1016/j.surg.2015.06.056
pubmed: 26456125
doi: 10.1016/j.surg.2015.06.056